Gene therapy holds great promise for treating cancers, but their clinical applications are being hampered due to uncontrolled gene delivery and expression. To develop a targeted, safe and efficient tumor therapy system, we constructed a tissue-specific suicide gene delivery system by using magnetic nanoparticles (MNPs) as carriers for the combination of gene therapy and hyperthermia on hepatoma. The suicide gene was hepatoma-targeted and hypoxia-enhanced, and the MNPs possessed the ability to elevate temperature to the effective range for tumor hyperthermia as imposed on an alternating magnetic field (AMF). The tumoricidal effects of targeted gene therapy associated with hyperthermia were evaluated in vitro and in vivo. The experiment demonstrated that hyperthermia combined with a targeted gene therapy system proffer an effective tool for tumor therapy with high selectivity and the synergistic effect of hepatoma suppression.
(Some figures may appear in colour only in the online journal) Hepatocellular carcinoma (HCC) is a common solid malignancy, causing 600 000 to 1 million deaths annually [1] . The main reasons contributing to the increase in HCC-related deaths are late diagnosis and the lack of effective therapeutic strategies. Only a few patients with HCC have the chance to receive surgical treatment, and tumor recurrence rates are very high. Radiotherapy and chemotherapy are usually inefficient due to the radio-insensitivity and multidrug resistance of HCC cells. Moreover, chemotherapy and radiotherapy often damage normal tissues and cause many side effects due to their nonselectivity. Thus, new treatments for HCC must be pursued.
Gene therapy has been a promise in HCC treatment for several years [2, 3] . However, the impediments to successful gene therapy are unsafe or inefficient delivery of genes to targeted sites and the nonspecific expression of therapeutic genes. Viral vectors are commonly used in gene therapy due to their high efficiency of gene delivery, but they often exhibit unwanted side effects, such as random integration and immunogenicity [4] . Recently, using functional nanoparticles (NPs) as a therapeutic gene carrier has received increasing attention for its potential to overcome viral delivery toxicity issues [5, 6] . In vivo research has demonstrated that the iron oxide NPs injected intravenously were mainly assembled in the liver and spleen a few days after injection [7, 8] and were almost entirely excreted from mice bodies after four months [8] . The results confirm the biocompatibility of magnetic nanoparticles (MNPs) and ensure the safety of their bioapplications. MNPs with appropriate surface modification could pass the genetic material through biological barriers in systemic delivery and transfer it into the cell nucleus efficiently without causing an immune response. The most suitable surface charges for NP application in gene delivery was the creation of a positive charge, which could enable a large amount of DNA molecules to strongly bind to the NPs [9] .
Due to their superior magnetic responsiveness, MNPs can transfer magnetic energy into heat and elevate the ambient temperature to a certain range when exposed to an alternating magnetic field (AMF), that was magnetic-induced heating or magnetic fluid hyperthermia [10] . The magneticinducing intratumoral heating could be localized in the tumor by magnetic targeting, thus avoiding damage to the healthy tissue around the tumor. For special microenvironments (such as chaotic vasculature, low perfusion, acidosis and hypoxia), solid malignancies were more sensitive to heating than healthy tissues [11] . It was reported that hyperthermia is an effective treatment for solid malignant tumors, particularly when combined with other treatments, such as chemotherapy or radiotherapy [12, 13] .
Development of a gene delivery system to specifically recognize and target tumor cells and to distinguish them from normal cells, especially in the same tissue or organ, is one of the most important issues regarding current gene delivery strategies [14] . Nanoparticles can pass through leaky tumor blood vessels and tend to accumulate more than in normal tissues. These phenomena are known as the enhanced permeability and retention (EPR) effect, which is the main passive tumor-targeting method [15] . Among active tumortargeting strategies, controlled and restricted gene expression in targeted tumor cells could minimize the side effects and improve the efficiency of gene therapy [16, 17] . Tissue-specific promoters have been applied to cancer gene therapy, which usually drive cytotoxic gene expression to inhibit cell proliferation and induce cell death. A tumor-specific gene expression system is an effective approach to targeting cancer cells. Regarding gene expression in hepatoma cells controlled by regulation of transcription, the α-fetoprotein (AFP) promoter is one of the most specific promoters used [18, 19] . Because the AFP gene was re-activated and re-expressed only when hepatocarcinogenesis occurred after human birth, the AFP promoter regulates the expression of the downstream gene only in HCC cells. Furthermore, beside therapeutic genes, reporter gene expression driven by a cancer-specific promoter is widely used for tumor molecular imaging, cancer metastasis monitoring and locating the gene delivery [20, 21] .
Most of the previous studies about tumor-specific gene therapy were focused on when and how to regulate gene expression. Gene expression can be regulated either before transcription (by regulating transcription factors and promoters) or after transcription (through RNA interference), and the gene carriers are usually viruses. For the first time, we tried to deliver a hepotoma-specific therapeutic gene by MNPs. The combination of nontoxic magnetic gene carriers and gene-regulated expression systems will increase the safety, specificity and efficiency of gene therapy, which also have the potential to combine hyperthermia with gene therapy for tumor treatment. In the current work, we constructed a suicide gene that was induced by an AFP promoter and hypoxia enhancement. Then, we delivered the genes into cells using MNPs. Meanwhile, magnetic-inducing heating on hepatomas was carried out. The tumoricidal effects of the system in vitro and in vivo were tested. The results of the experiments provide a potential new modality for tumor treatment.
Materials and methods

Main apparatus and reagents
For transmission electron microscopy (TEM), a JEM-200CX model (JEOL, Japan) was used, and for scanning electron microscopy (SEM) was an S-3400N II model (Hitachi, Japan) was used. Fourier transform infrared spectrometry (FTIR) spectra were purchased from NEXUS870 (NICOLET, USA). The XRD used was the X' TRA model (ARL, Swiss).The zeta potential analyzer of NPs was purchased from the Zeta Plus particle sizing analyzer (Brookhaven Instruments, USA).
The Dulbecco minimum essential medium (DMEM) medium was purchased from Gibco-Invitrogen Corp. (USA). 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazoliun bromide (MTT) and polyethylenimine (PEI) was purchased from Sigma (USA). All the reagents used, including ferric chloride and NH 3 · H 2 O (Aladdin, Shanghai, China), were of analytical grade.
Plasmid construction
The sequence of the human AFP gene 0.3 kb promoter containing the core sequence was synthesized by Yingrun Corporation (Changsha, China), which was inserted into the MluI-HindIII site of the pcDNA3.1 vector, replacing the CMV promoter, which created the pcDNA3.1-AFPp vector. The segment of 5HRE (5 copies of HREs) was released from pUC57-5HRE (Yingrun Corporation, Changsha, China) by MluI digestion and inserted into the MluI site of pCDNA3. ) using an ultrasonic bath for 60 min, then Fe 3 O 4 NPs were magnetically separated, washed with water several times, and re-suspended in a PBS buffer (pH7.0, 50 ml) with sonication. PEI (2.0 ml of a 20% aqueous solution) was added drop-wise into the mixture and mechanically stirred for 24 h in a 30°C water bath to produce stable PEI-coated Fe 3 O 4 colloid. The NPs were magnetically recovered and washed with acetone five times to remove residual PEI, and finally dried in a vacuum. MNPs was carried out with powder x-ray diffraction (XRD) analysis. FTIR spectra were obtained from powder samples on a FTIR spectrometer. The Zeta potential analyzer of NPs was purchased from a Zeta Plus particlesizing analyzer (Brookhaven Instruments, USA).
Heating test of PEI-Fe 3 O 4 MNPs
The PEI-Fe 3 O 4 MNPs were diluted in HEPES buffer (10 mM, pH 7.0) at 0.5, 1.0, 1.5 mg ml −1 concentration, respectively, and the mixtures were placed in a flat-bottomed cuvette into the center of the hyperthermia coil of the AMF (f = 230 kHz, I = 30 A) for 60 min. The temperature was measured at 5 min intervals.
Gel retardation assay
p[HRE]AFP-HSVTK-MNPs complexes at various NP:DNA weight ratios were prepared and incubated for 30 min. Then, the DNA-MNPs complexes were added to the wells (10 μg of DNA per lane) of a 0.8% agarose gel, and run at 100 V for 1 h. Images were obtained on a gel-imaging analysis system, the JS-680D (Shang Hai Peiqing Science and Technology Corporation, China).
Cell culture
Human HCC lines AFP-positive HepG2, AFP-negative SMMC7721, human colorectal carcinoma (Lovo) and fibroblast (L929) lines were maintained in DMEM supplemented with 10% fetal calf serum. All cell lines were incubated in a humidified 5% CO 2 atmosphere at 37°C (Normoxia). Hypoxia was induced by culturing cells in an incubator containing 1% O 2 , 5% CO 2 and 94% N 2 at 37°C.
Cell transfection mediated by PEI-Fe 3 O 4 magnetic nanoparticles
The NP-DNA transfection complexes need to be formed before adding to cells. The plasmid and PEI-Fe 3 O 4 MNPs were diluted in a DMEM base medium (without supplements) separately, then gently mixed together by pipetting, and incubated for 30 min in room temperature. The mass ratio of plasmid and PEI-Fe 3 O 4 NPs in the transfection complexes was 8:1 (NP:DNA weight ratio). At 24 h after cell seeding, the medium was removed and cells were washed by PBS (pH7.4) three times, and then drop-wise added particle-DNA transfection complexes, and the medium was replaced with fresh medium (no particles or DNA) at 6 h post addition.
Evaluation of HCC cells-specific cytotoxicity of GCV/p [HRE]AFP-HSVTK MNPs in vitro
Hepatoma cell lines (HepG2, SMMC7721) and nonhepatoma cell lines (L929, LOVO) were used for the assays. Cells (5 × 10 3 /well) were incubated in 96-well multiplates, then divided into three teams with different treatments: (1) a transfection group, where the cells were transfected by p [HRE]AFP-HSVTK MNPs; (2) a GCV-only control well (untransfected, incubated with GCV at concentrations of 10 μg ml −1 ); (3) a negative control (with no treatment and routinely incubated). Cells of teams (1) and (2) were exposed to GCV at concentrations of 10 μg ml −1 , and all the cells were incubated in the case of normoxia or hypoxia. Under hypoxia, cells were exposed to 1% O 2 for 24 h every two days. After four days' culture, MTT assays were performed, and the absorbance of each well was measured at a wavelength of 492 nm using an MK3 Multiskan microplate reader (Thermo, Finland). All the assays had eight repeats, and we took the mean values.
Establishment of HCC xenografts nude mice model
Healthy female BALC/c nude mice, aged four weeks, weighing 18-20 g were used for the experiment. The animal experiments were approved by the Animal Care Committee of Jiangsu Province and were performed in accordance with institutional guidelines. All the mice were maintained in the Sterile Barrier System of the Medical School, Southeast University, China. Exponentially growing HepG2 cells (2 × 10 6 ) were injected subcutaneously into the limbs of the mice to establish the hepatoma xenografts models.
HCC specific expression of luciferase reporter gene delivered by MNPs in vitro and in vivo
Dual-luciferase reporter assays were carried out to test the transcriptional efficiency of recombinant plasmids in Hepatoma cell lines (HepG2, SMMC7721) and nonhepatoma cell lines (L929, LOVO). The co-transfection was performed using 4 μg of the luciferase fusion plasmid p[HRE]AFP-luc and 0.4 μg of pRL-TK, a Renilla luciferase control vector (Promega, USA) with 32 μg PEI-Fe 3 O 4 MNPs per well in sixwell multiplates by NP transfection methods. At 6 h after transfection, the cells were incubated with fresh medium under either normoxic or hypoxic conditions for 48 h. Then the cells were harvested and the dual-luciferase reporter assays (Promega, USA) were carried out in a multifunction microplate reader (TriStar LB941, Berthold, Germany). All the assays had three repeats, and the average values of each cell lines were adopted.
An IVIS imaging system (Xenogen, USA) was used for bioluminescent imaging in vivo. The mice baring xenografts were injected with 100 μl nanoparticle-DNA transfection complexes via the tail vein, which consisted of 80 μg PEIMNPs and 10 μg p[HRE]AFP-luc DNA, formed 30 min prior to injection. The control animals were injected with 100 μl normal saline via the tail vein. Seven days later, each mouse was injected intraperitoneally with 25 μl D-luciferin sodium salt solution (15 mg ml −1 , Goldbio Technology, USA) and the bioluminescent signal was acquired after 10 min. To measure the toxicity of the injection, the animals were killed 21-days post-injection and the major organs (heart, lung, liver, kidney and spleen) were collected and fixed with 10% paraformaldehyde. Then the organs were embedded in paraffin, sectioned at 10 μm, stained with hematoxylin and eosin, and were observed by light microscopy. AFP-HSVTK, the cells were added GCV at final concentration of 10 μg ml −1 and incubated for 48 h (hypoxia for 24 h followed by normoxia for another 24 h); (4) Gene therapy combined with heating group: the cells were heating for 1 h (as the hyperthermia group) at 24 h post transfection, then incubated with GCV at final concentration of 10 μg ml −1 for 48 h (hypoxia for 24 h then normoxia for another 24 h). The cell growth and proliferation of each group were measured by an MTT assay, and the percentage of the cell growth inhibition rate (IR) was calculated. All the groups have eight repeat wells.
Where A is absorbance from cells with different treatments and B is absorbance from the negative control cells. The cells flow cytometry assay was used to measure apoptosis and necrosis for each treatment group. HepG2 cells were seeded in 50 ml culture bottles and divided into four groups treated respectively as mentioned above. (2) and (4) were heated on a high-frequency heater coil plate (f = 230 kHz, I = 30 A) for 60 min on the day 3 and 6 post injection. The temperature of the tumors and rectums of the mice were measured at 5 min intervals during hyperthermia using an infrared thermometer (ZyTemp-TN18 model, China). The tumor volumes were calculated from the formula
Where A is the longer and B is the shorter lateral diameter of the tumor. All the mice were killed four weeks after treatment. The tumors were dissected and their mass was measured. Morphology of the tumor tissue was examined by TEM.
Statistical analysis
Values are shown as mean ± standard deviation (SD). The data were analyzed with the SPSS statistics program. Comparisons of quantitative data were analyzed using one-way analysis of variance (ANOVA) for multiple groups. A p value of <0.05 was considered statistically significant.
Results
Construction and identification of the recombinant vectors
The recombinant eukaryotic expression vector p[HRE]AFP-HSVTK and p[HRE]AFP-luc were analyzed by restriction endonuclease digestion and sequencing (Sangon, China). The segments (5HRE, 0.3 kb AFP promoter, HSV-TK, luciferase) were all inserted into the correct sites of pcDNA 3.1, which were confirmed by digestion gel electrophoresis (figure 1), and their sequences were identical with the corresponding published data. Thus, the recombinant vector p[HRE]AFP-HSVTK and the luciferase reporter plasmid p[HRE]AFP-luc were confirmed.
Characterizations of PEI-Fe 3 O 4 MNPs
The morphology of PEI- MNPs at a concentration of 0.5, 1.0, 1.5 mg ml −1 was carried out on an AMF (f = 230 kHz, I = 30 A ). When exposed to the AMF, the temperature of PEI-Fe3O4 MNPs at all three concentrations increased rapidly within the first 25 min from 25°C to above 4°C, then rose more slowly, and holding at 41-50°C in the following 30 min ( figure 3 ). The rate of the temperature increase and the highest temperature the NPs could hold were concentration-dependent. To avoid unwanted necrosis caused by rapid temperature elevation and achieve effective therapy temperatures (42-44°C), we chose the concentration of 1 mg ml −1 for magnetic heating in vitro and in vivo.
The gel retardation assay
By agarose gel electrophoresis, the DNA binding affinity of MNPs was tested at various weight ratios. As shown in figure 4 , the complete retardation was observed above the particle/DNA weight ratio of 2:1, which indicates that DNA was well packaged in the complexes and protected by the NPs, which provided the possibility of successful transfection. Agarose gel electrophoresis was used to test DNA retention in p[HRE]AFP-HSVTK loaded MNPs prepared at various particles. DNA weight ratios after 0.5 h standing in a HEPES buffer (10 mM, pH 7.0).
HCC-targeted cytotoxicity of GCV/p[HRE]AFP-HSVTK MNPs on cells
To evaluate the specific antitumor effect that GCV induces by p[HRE]AFP-HSVTK MNPs, we tested the cell proliferation of transfected hepatoma cells (HepG2 and SMMC7721) and nonhepatoma cells (L9292 and LOVO) exposed to GCV at concentrations of 10 μg ml −1 by MTT assays. After incubation under either hypoxia or normoxia conditions for four days, the optical density of each cell line was measured and shown as mean ± SD (figure 5). The transfected nonhepatoma cells (L929 and LOVO) hardly exhibited sensitivity to GCV versus the negative control (p > 0.05) under normoxia or hypoxia. The proliferation of fibroblast cell line L929 was restrained significantly under hypoxia, which was GCVindependent. Zhang et al reported the similar results that the proliferation of fibroblast cells was declined when incubated under hypoxia for over 48 h [22] . The main reason for this was that excessive HIF accumulated in the cells, along with the fibroblast's weaker tolerance of hypoxia. The transfected hepatoma cells (HepG2 and SMMC7721) exhibited sensitivity to GCV versus the negative control (p < 0.001), and the proliferation significantly declined under hypoxia (p < 0.001). The results exhibited p[HRE]AFP-HSVTK-loaded MNPs induced specific and hypoxia enhanced cytotoxicity of GCV to HCC cells.
The HCC-specific expression of luciferase reporter gene in vitro and in vivo
The dual-luciferase assays on different cells were used to quantity evaluated the hepatoma-specific transcription of the recombinant plasmid. The relative activity of luciferase was obtained by luciferase activity divided by renilla luciferase activity corresponding for every cell line, and all assays had three repeats. As shown in figure 6 , the relative expression of luciferase in hypoxia HepG2 cells was 2.8 times greater than that of the cells incubated in the normoxia condition. In hypoxic SMMC7721 cells, the relative expression of luc increased 5.5 times more than normoxic HCC cells. In nonhepatoma cells L929 and Lovo, the expression of luciferase was almost undetectable, both under hypoxia and normoxia conditions.
The nude mice baring the HepG2 xenografts were injected with p[HRE]AFP-luc NP transfection complexes via the tail vein to evaluate the targeted reporter gene expression in vivo. Seven days after the injection, HCC-specific luciferase expression was demonstrated in a bioluminescent image (BLI), as shown in figure 7 . The results indicate that the hybrid promoter [HRE]AFP induced a HCC-specific expression of downstream genes and the successful delivery of genes to their targeted sites by MNPs in vivo. The histological study of injected animal tissues evaluated the toxicity of the targeted gene delivery by MNPs. Based on the histological analysis of animal tissues, no apparent histopathological abnormalities or lesions were found in the main organs, such as the heart, liver, kidneys, lungs and spleen (figure 8).
(1) The white arrow indicated the HepG2 xenograft tumor of the mouse. HepG2 cells were divided into four groups: (1) negative control group; (2) hyperthermia alone group; (3) gene therapy alone group; (4) gene therapy combined with heating group. Each group was treated as described above. The cell proliferations of all the four groups were measured by MTT assay after incubation for 48 h. As shown in table 1, the hyperthermo-gene-combined treatment exhibited superior cytotoxity effect on HepG2 cells compared to the other two groups, and the IR was 76.03%. For the two single-modality treatment groups, the IR of hyperthermia alone group was 42.31%, and the IR of gene/prodrug therapy group was 47.75%. The data indicate that the hyperthermo-gene combined treatment was much more effective than the other groups.
To test whether the suppression of tumor cell growth was caused by apoptosis and necrosis, the HepG2 cells of each treatment group were labeled by A-V and PI to analyze apoptosis and necrosis by flow cytometry. The single positive of A-V stands for apoptosis cell, and both positive of A-V and PI stands for necrosis cell. As shown in figure 9 , the apoptosis and necrosis rate of the hyperthermo-gene combined treatment group were 34.05% and 32.48%, which showed that combined treatment achieved the best tumor inhibition effect compared with each individual therapy. In contrast, the apoptosis and necrosis rate of the hyperthermia alone group were 14.41% and 8.44%. The apoptosis and necrosis rate of the gene therapy alone group were 25.06% and 11.64%. The results of the flow cytometric analysis were consistent with the inhibition of cell proliferation assay.
In vivo experiments the surface temperature of tumors injected with MNPs increased about 7°C above the skin temperature within 25 min of exposure to an AMF (f = 230 kHz, I = 30 A). In contrast, the rectal temperature did not increase significantly (figure 10). The tumor growth rate, tumor volume and mass of the combined treatment group was significantly less than the other two treatment groups, as shown in figure 11 . The results were consistent with the in vitro assays.
To observe the sub-cellular structure of tumors from the combined treatment group, the tumor was observed by TEM. We saw the ultra-structure of typical apoptosis cells, which exhibited chromatin condensation, chromatin margination and cytoplasma vacuolation (figure 12).
Discussion
Among gene therapy strategies, the combination of herpes simplex virus thymidine kinase (HSV-tk) with ganciclovir (GCV) exhibited the highest efficacy for targeted cancer therapy. The antiviral drug GCV is nontoxic to mammalian cells, but within cells that could be phosphorylated by HSV-tk and the phosphorylated products inhibits DNA synthesis, thus leading host cells apoptosis [23] . The AFP promoter is tissuespecific, which mediated targeted gene expression only in HCC cells. The HSV-tk gene driven by AFP promoter was not expressed in normal cells, so the normal tissues were insensitive to GCV and avoided damage. Under hypoxia, the hypoxia-inducible factor-1 (HIF-1) of cells was accumulated and bound to hypoxia response elements (HREs), boosting the transcription level of hypoxia response genes, which adapted the carcinoma cells to a hypoxia environment but retrained the proliferation of normal cells [24, 25] . So the decreased fibroblast proliferation (L929 cell line) under hypoxia (p < 0.001) was independent to the cytotoxic effect of HSV-TK/GCV. Connecting the HREs as a hypoxic enhancer with the AFP promoter could greatly promote transcription efficiency in tumor cells, while providing additional specificity of gene expression in the tumor hypoxic environment [26] . The availability of sensitive and specific reporter genes is an efficient tool for monitoring the gene expression in a delivery system for gene therapy. For its high sensitivity, lowcost and the tight coupling of the Luc protein concentration with luminescence output, the firly luciferase was one of the most commonly used reporter genes [27, 28] . In our system, the luciferase fusion genes delivered by MNPs was hepatomaspecific when expressed in vitro and in vivo, and histological analysis of the major organs of mice exhibited no visual inflammations or lesions caused by systemic administration. These results indicated that the hepatoma-targeted gene delivery system was relatively safe and that MNPs were potential efficient carriers for gene therapy. The tumor-specific reporter gene expression confirmed the delivery of MNPs and may serve as a tumor noninvasive imaging system for the early diagnosis of tumors.
Cancer is one of the most devastating diseases, and single modality treatments are limited and not able to cure cancer alone. Studies in recent years' showed that multimodal therapy always exhibited more effectiveness in tumor suppression than single-modality treatment [29] [30] [31] . Combination treatment has been investigated for its synergistic effect, which may dramatically improve outcomes while reducing the side effects of each single treatment modality. Hyperthermia, the procedure of raising the temperature of tumor-loaded tissue to 40-43°C, is often applied as an adjunctive therapy that can accompany various established cancer treatment [32] . NMF hyperthermia on a tumor is injecting MNPs directly into a malignant tumor and the NPs were excited and heated in an AMF, which is locally precise, target-specific and temperature controllable, avoiding over-heating normal tissues around the tumor [33] . In the current study, the tumor-eliminating rate by magnetic fluid hyperthermia was greatly enhanced when combined with gene therapy. However, the mechanism of the combined treatment is uncertain now and the possibilities may be as follows. Hyperthermia in combined oncological treatments was thought to affect sensitivity to other treatments mainly through microenvironmental factors [34] . In hyperthermia treatments, the tumor tissue is elevated above 40°C, the integrity of the cell membrane was damaged and the permeability increased, which favored the absorption of predrug. Thermotherapy suppressed the repair of DNA damage by gene therapy, and rouses some dormant cells in G0 phase and made them susceptible to chemotherapy [35] . Heating has direct cytotoxicity effects (necrosis, coagulation or carbonation) or induced tumor cells apoptosis, which contributed to the tumor-cell-eliminating effects.
The experiment demonstrated that the hepatoma-specific therapeutic gene delivery system have the perspective to realize the combination of targeting gene therapy and magnetically induced heating on HCC treatment, and perhaps a potential option for tumor therapy.
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